
Conference Coverage
about 23 hours ago
Keytruda After Kidney Cancer Surgery Lowers Risk of Death by 30%Latest Content

Rasonque for Pancreatic Cancer: Patients Discuss Benefits, Risks and Access

Sac-TMT Plus Keytruda Improves Outcomes in PD-L1-Negative Lung Cancer

Palliative Care vs. Hospice With Cancer: Your Questions Answered

App Provides Educational Resources for Patients With Urologic Cancers

After Breast Cancer, Thanksgiving Is No Longer Just One Day

Shorts










Videos
All News

Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.

HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.

After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).

For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.

A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.

After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.

From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.

Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.

A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.

In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.

Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.

Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.

An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.

The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.































